Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label Multi-Center Study Of Single Agent Larotaxel (XRP9881) Compared To Continuous Administration of 5-FU For The Treatment Of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen

NCT00417209 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00417209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00417209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label Multi-Center Study Of Single Agent Larotaxel (XRP9881) Compared To Continuous Administration of 5-FU For The Treatment Of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2006
Completion date
November 30, 2009
Enrollment
408 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasms